image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 4.21
2.43 %
$ 674 M
Market Cap
-421.0
P/E
1. INTRINSIC VALUE

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc.[ Read More ]

The intrinsic value of one IRWD stock under the base case scenario is HIDDEN Compared to the current market price of 4.21 USD, Ironwood Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRWD

image
FINANCIALS
443 M REVENUE
7.83%
209 M OPERATING INCOME
-16.50%
-1 B NET INCOME
-572.50%
183 M OPERATING CASH FLOW
-33.00%
-1.03 B INVESTING CASH FLOW
-754545.59%
277 M FINANCING CASH FLOW
216.67%
91.6 M REVENUE
-2.97%
25.6 M OPERATING INCOME
-5.21%
3.65 M NET INCOME
523.95%
9.88 M OPERATING CASH FLOW
-70.46%
-16 K INVESTING CASH FLOW
72.41%
-27.2 M FINANCING CASH FLOW
45.00%
Balance Sheet Decomposition Ironwood Pharmaceuticals, Inc.
image
Current Assets 233 M
Cash & Short-Term Investments 92.2 M
Receivables 129 M
Other Current Assets 12 M
Non-Current Assets 238 M
Long-Term Investments 0
PP&E 18.2 M
Other Non-Current Assets 220 M
Current Liabilities 276 M
Accounts Payable 7.83 M
Short-Term Debt 203 M
Other Current Liabilities 65.6 M
Non-Current Liabilities 541 M
Long-Term Debt 513 M
Other Non-Current Liabilities 28.4 M
EFFICIENCY
Earnings Waterfall Ironwood Pharmaceuticals, Inc.
image
Revenue 443 M
Cost Of Revenue 1.58 M
Gross Profit 441 M
Operating Expenses 232 M
Operating Income 209 M
Other Expenses 1.21 B
Net Income -1 B
RATIOS
99.64% GROSS MARGIN
99.64%
47.21% OPERATING MARGIN
47.21%
-226.37% NET MARGIN
-226.37%
289.42% ROE
289.42%
-212.76% ROA
-212.76%
64.69% ROIC
64.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ironwood Pharmaceuticals, Inc.
image
Net Income -1 B
Depreciation & Amortization 1.58 M
Capital Expenditures -273 K
Stock-Based Compensation 32 M
Change in Working Capital 11.3 M
Others 1.07 B
Free Cash Flow 183 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ironwood Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for IRWD of $12.2 , with forecasts ranging from a low of $5 to a high of $18 .
IRWD Lowest Price Target Wall Street Target
5 USD 18.76%
IRWD Average Price Target Wall Street Target
12.2 USD 190.97%
IRWD Highest Price Target Wall Street Target
18 USD 327.55%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Ironwood Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.52 M USD 7
6-9 MONTHS
0 USD 0
9-12 MONTHS
4.42 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
160 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 12, 2024
Sell 42.3 K USD
John Minardo
Chief Legal Officer
- 9910
4.27 USD
3 months ago
Aug 12, 2024
Sell 13.3 K USD
Silver Ronald
Principal Accounting Officer
- 3107
4.27 USD
5 months ago
Jun 10, 2024
Sell 143 K USD
McHugh Julie
Director
- 22766
6.29 USD
5 months ago
Jun 06, 2024
Sell 283 K USD
Moukheibir Catherine
Director
- 44426
6.36 USD
5 months ago
Jun 07, 2024
Sell 235 K USD
Moukheibir Catherine
Director
- 35574
6.61 USD
5 months ago
May 20, 2024
Sell 436 K USD
MCCOURT Thomas A
Chief Executive Officer
- 67618
6.45 USD
5 months ago
May 20, 2024
Sell 147 K USD
Davis Andrew
SVP, Chief Business Officer
- 22725
6.45 USD
5 months ago
May 20, 2024
Sell 104 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 16128
6.45 USD
5 months ago
May 20, 2024
Sell 112 K USD
John Minardo
Chief Legal Officer
- 17404
6.45 USD
8 months ago
Mar 06, 2024
Bought 60.2 K USD
Duane Jon R
Director
+ 6920
8.7 USD
8 months ago
Mar 04, 2024
Bought 100 K USD
Emany Sravan Kumar
SVP, Chief Financial Officer
+ 10684
9.38 USD
9 months ago
Feb 12, 2024
Sell 722 K USD
John Minardo
Chief Legal Officer
- 47380
15.24 USD
9 months ago
Feb 12, 2024
Sell 589 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 38618
15.24 USD
9 months ago
Feb 12, 2024
Sell 121 K USD
Silver Ronald
Principal Accounting Officer
- 7908
15.24 USD
9 months ago
Feb 12, 2024
Sell 150 K USD
Davis Andrew
SVP, Chief Business Officer
- 9846
15.24 USD
9 months ago
Feb 12, 2024
Sell 2.7 M USD
MCCOURT Thomas A
Chief Executive Officer
- 177164
15.24 USD
11 months ago
Dec 14, 2023
Sell 111 K USD
Kessler Marla L
Director
- 9926
11.19 USD
11 months ago
Nov 20, 2023
Sell 31.9 K USD
Davis Andrew
SVP, Chief Business Officer
- 3287
9.69 USD
1 year ago
Sep 15, 2023
Bought 300 K USD
Emany Sravan Kumar
SVP, Chief Financial Officer
+ 36072
8.32 USD
1 year ago
Aug 14, 2023
Sell 19.8 K USD
Silver Ronald
Principal Accounting Officer
- 1976
10.04 USD
1 year ago
Aug 14, 2023
Sell 70.7 K USD
John Minardo
Chief Legal Officer
- 7045
10.04 USD
1 year ago
May 30, 2023
Sell 285 K USD
MCCOURT Thomas A
Chief Executive Officer
- 26632
10.7 USD
1 year ago
May 22, 2023
Sell 104 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 10324
10.12 USD
1 year ago
May 22, 2023
Sell 63.8 K USD
Davis Andrew
SVP, Chief Business Officer
- 6305
10.12 USD
1 year ago
May 22, 2023
Sell 364 K USD
MCCOURT Thomas A
Chief Executive Officer
- 36000
10.12 USD
1 year ago
May 08, 2023
Sell 225 K USD
MCCOURT Thomas A
Chief Executive Officer
- 21148
10.62 USD
1 year ago
Mar 27, 2023
Sell 492 K USD
MCCOURT Thomas A
Chief Executive Officer
- 46129
10.67 USD
1 year ago
Mar 03, 2023
Sell 379 K USD
MCCOURT Thomas A
Chief Executive Officer
- 33756
11.22 USD
1 year ago
Feb 27, 2023
Sell 33.4 K USD
Silver Ronald
Principal Accounting Officer
- 2929
11.41 USD
1 year ago
Feb 28, 2023
Sell 34.5 K USD
Silver Ronald
Principal Accounting Officer
- 3049
11.31 USD
1 year ago
Feb 27, 2023
Sell 153 K USD
Rickard Jason
SVP, Chief Operating Officer
- 13438
11.41 USD
1 year ago
Feb 27, 2023
Sell 37.7 K USD
Rickard Jason
SVP, Chief Operating Officer
- 3308
11.41 USD
1 year ago
Feb 28, 2023
Sell 158 K USD
Rickard Jason
SVP, Chief Operating Officer
- 13987
11.31 USD
1 year ago
Feb 28, 2023
Sell 38.9 K USD
Rickard Jason
SVP, Chief Operating Officer
- 3442
11.31 USD
1 year ago
Feb 27, 2023
Sell 292 K USD
MCCOURT Thomas A
Chief Executive Officer
- 25595
11.41 USD
1 year ago
Feb 27, 2023
Sell 50.3 K USD
MCCOURT Thomas A
Chief Executive Officer
- 4409
11.41 USD
1 year ago
Feb 28, 2023
Sell 301 K USD
MCCOURT Thomas A
Chief Executive Officer
- 26639
11.31 USD
1 year ago
Feb 28, 2023
Sell 51.9 K USD
MCCOURT Thomas A
Chief Executive Officer
- 4588
11.31 USD
1 year ago
Feb 27, 2023
Sell 81.5 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 7146
11.41 USD
1 year ago
Feb 27, 2023
Sell 26.5 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 2322
11.41 USD
1 year ago
Feb 28, 2023
Sell 84.1 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 7438
11.31 USD
1 year ago
Feb 28, 2023
Sell 27.3 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 2416
11.31 USD
1 year ago
Feb 27, 2023
Sell 37.4 K USD
John Minardo
Chief Legal Officer
- 3282
11.41 USD
1 year ago
Feb 28, 2023
Sell 38.6 K USD
John Minardo
Chief Legal Officer
- 3415
11.31 USD
1 year ago
Feb 27, 2023
Sell 20 K USD
Davis Andrew
SVP, Chief Business Officer
- 1751
11.41 USD
1 year ago
Feb 28, 2023
Sell 20.6 K USD
Davis Andrew
SVP, Chief Business Officer
- 1822
11.31 USD
1 year ago
Jan 05, 2023
Sell 1.34 M USD
MCCOURT Thomas A
Chief Executive Officer
- 110962
12.07 USD
1 year ago
Dec 14, 2022
Sell 335 K USD
Rickard Jason
SVP, Chief Operating Officer
- 27000
12.39 USD
1 year ago
Nov 21, 2022
Sell 76 K USD
Emany Sravan Kumar
SVP, Chief Financial Officer
- 6578
11.56 USD
1 year ago
Nov 21, 2022
Sell 7.88 K USD
Silver Ronald
Principal Accounting Officer
- 682
11.56 USD
1 year ago
Nov 21, 2022
Sell 38.6 K USD
Davis Andrew
SVP, Chief Business Officer
- 3335
11.56 USD
2 years ago
Oct 03, 2022
Sell 197 K USD
MCCOURT Thomas A
Chief Executive Officer
- 18899
10.41 USD
2 years ago
Sep 01, 2022
Sell 282 K USD
MCCOURT Thomas A
Chief Executive Officer
- 26446
10.65 USD
2 years ago
Aug 15, 2022
Sell 23.7 K USD
Silver Ronald
Principal Accounting Officer
- 2014
11.77 USD
2 years ago
Aug 15, 2022
Sell 11.7 K USD
Rickard Jason
SVP, Chief Operating Officer
- 994
11.77 USD
2 years ago
Aug 15, 2022
Sell 86.3 K USD
John Minardo
Chief Legal Officer
- 7330
11.77 USD
2 years ago
Aug 11, 2022
Sell 825 K USD
Currie Mark G
director:
- 70000
11.78 USD
2 years ago
Aug 08, 2022
Sell 317 K USD
Rickard Jason
SVP, Chief Operating Officer
- 27200
11.64 USD
2 years ago
Aug 08, 2022
Sell 25.8 K USD
Rickard Jason
SVP, Chief Operating Officer
- 2236
11.56 USD
2 years ago
Aug 08, 2022
Sell 212 K USD
Rickard Jason
SVP, Chief Operating Officer
- 18041
11.75 USD
2 years ago
Aug 01, 2022
Sell 264 K USD
MCCOURT Thomas A
Chief Executive Officer
- 23229
11.35 USD
2 years ago
Jun 30, 2022
Sell 231 K USD
MCCOURT Thomas A
Chief Executive Officer
- 19959
11.58 USD
2 years ago
Jun 14, 2022
Sell 88.7 K USD
Kessler Marla L
director:
- 7610
11.65 USD
2 years ago
Jun 07, 2022
Sell 2.29 M USD
Currie Mark G
director:
- 190383
12.01 USD
2 years ago
May 23, 2022
Sell 29.8 K USD
MCCOURT Thomas A
Chief Executive Officer
- 2587
11.5 USD
2 years ago
May 23, 2022
Sell 252 K USD
MCCOURT Thomas A
Chief Executive Officer
- 21873
11.5 USD
2 years ago
May 23, 2022
Sell 136 K USD
MCCOURT Thomas A
Chief Executive Officer
- 11848
11.5 USD
2 years ago
May 23, 2022
Sell 1.38 K USD
Silver Ronald
Principal Accounting Officer
- 120
11.5 USD
2 years ago
May 23, 2022
Sell 36 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 3130
11.5 USD
2 years ago
May 23, 2022
Sell 85.7 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 7453
11.5 USD
2 years ago
May 23, 2022
Sell 8.94 K USD
Rickard Jason
SVP, Chief Operating Officer
- 777
11.5 USD
2 years ago
May 23, 2022
Sell 147 K USD
Rickard Jason
SVP, Chief Operating Officer
- 12760
11.5 USD
2 years ago
Mar 24, 2022
Sell 38.6 K USD
Silver Ronald
Principal Accounting Officer
- 3031
12.75 USD
2 years ago
Mar 14, 2022
Sell 233 K USD
McHugh Julie
director:
- 20000
11.67 USD
2 years ago
Feb 28, 2022
Sell 4.82 K USD
Silver Ronald
Principal Accounting Officer
- 448
10.77 USD
2 years ago
Feb 28, 2022
Sell 6.89 K USD
Silver Ronald
Principal Accounting Officer
- 640
10.77 USD
2 years ago
Feb 28, 2022
Sell 12.4 K USD
Silver Ronald
Principal Accounting Officer
- 1150
10.77 USD
2 years ago
Feb 28, 2022
Sell 20.9 K USD
MCCOURT Thomas A
Chief Executive Officer
- 1942
10.77 USD
2 years ago
Feb 28, 2022
Sell 108 K USD
MCCOURT Thomas A
Chief Executive Officer
- 10026
10.77 USD
2 years ago
Feb 28, 2022
Sell 215 K USD
MCCOURT Thomas A
Chief Executive Officer
- 19970
10.77 USD
2 years ago
Feb 28, 2022
Sell 178 K USD
MCCOURT Thomas A
Chief Executive Officer
- 16486
10.77 USD
2 years ago
Feb 28, 2022
Sell 14.7 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 1367
10.77 USD
2 years ago
Feb 28, 2022
Sell 31.4 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 2911
10.77 USD
2 years ago
Feb 28, 2022
Sell 55.6 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 5161
10.77 USD
2 years ago
Feb 28, 2022
Sell 41 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 3804
10.77 USD
2 years ago
Feb 28, 2022
Sell 47 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 4364
10.77 USD
2 years ago
Feb 28, 2022
Sell 20.6 K USD
Rickard Jason
SVP, Chief Operating Officer
- 1913
10.77 USD
2 years ago
Feb 28, 2022
Sell 33.9 K USD
Rickard Jason
SVP, Chief Operating Officer
- 3150
10.77 USD
2 years ago
Feb 28, 2022
Sell 64.9 K USD
Rickard Jason
SVP, Chief Operating Officer
- 6022
10.77 USD
2 years ago
Feb 28, 2022
Sell 119 K USD
Rickard Jason
SVP, Chief Operating Officer
- 11057
10.77 USD
2 years ago
Feb 28, 2022
Sell 73.5 K USD
Rickard Jason
SVP, Chief Operating Officer
- 6820
10.77 USD
2 years ago
Dec 22, 2021
Sell 529 K USD
MCCOURT Thomas A
Chief Executive Officer
- 46327
11.41 USD
2 years ago
Dec 16, 2021
Sell 305 K USD
Rickard Jason
SVP, Chief Operating Officer
- 27000
11.28 USD
2 years ago
Dec 14, 2021
Sell 110 K USD
McHugh Julie
Director
- 10000
11.02 USD
2 years ago
Nov 23, 2021
Sell 610 K USD
MCCOURT Thomas A
Chief Executive Officer
- 52644
11.58 USD
2 years ago
Nov 23, 2021
Sell 4.94 K USD
Rickard Jason
SVP, Chief Operating Officer
- 427
11.58 USD
2 years ago
Nov 23, 2021
Sell 194 K USD
Rickard Jason
SVP, Chief Operating Officer
- 16766
11.58 USD
2 years ago
Nov 23, 2021
Sell 160 K USD
Shetzline Michael
CMO,SVP,Head-Res&Drug
- 13776
11.58 USD
2 years ago
Nov 23, 2021
Sell 8.67 K USD
Silver Ronald
Principal Accounting Officer
- 749
11.58 USD
2 years ago
Nov 23, 2021
Sell 8.26 K USD
Silver Ronald
Principal Accounting Officer
- 713
11.58 USD
3 years ago
Aug 16, 2021
Sell 7.64 K USD
Silver Ronald
Principal Accounting Officer
- 567
13.48 USD
3 years ago
Aug 16, 2021
Sell 9.17 K USD
Rickard Jason
SVP, Chief Operating Officer
- 680
13.48 USD
3 years ago
Jun 14, 2021
Sell 273 K USD
Currie Mark G
Director
- 23571
11.59 USD
3 years ago
May 24, 2021
Sell 25.4 K USD
Shetzline Michael
CMO, SVP & Head of Drug Devt.
- 2077
12.25 USD
3 years ago
May 24, 2021
Sell 6.32 K USD
Rickard Jason
SVP, Chief Operating Officer
- 516
12.25 USD
3 years ago
May 24, 2021
Sell 21 K USD
MCCOURT Thomas A
President and Interim CEO
- 1716
12.25 USD
3 years ago
Mar 10, 2021
Bought 790 K USD
DENNER ALEXANDER J
director, 10 percent owner:
+ 75000
10.54 USD
3 years ago
Mar 08, 2021
Bought 1.54 M USD
DENNER ALEXANDER J
director, 10 percent owner:
+ 150000
10.3 USD
3 years ago
Mar 05, 2021
Bought 1.75 M USD
DENNER ALEXANDER J
director, 10 percent owner:
+ 175000
10.01 USD
3 years ago
Mar 04, 2021
Bought 2.5 M USD
DENNER ALEXANDER J
director, 10 percent owner:
+ 250000
10 USD
3 years ago
Mar 03, 2021
Bought 3.51 M USD
DENNER ALEXANDER J
director, 10 percent owner:
+ 350000
10.02 USD
3 years ago
Mar 02, 2021
Bought 4.78 M USD
DENNER ALEXANDER J
Director
+ 500000
9.56 USD
3 years ago
Mar 01, 2021
Bought 3.31 M USD
DENNER ALEXANDER J
Director
+ 344900
9.6 USD
3 years ago
Feb 26, 2021
Bought 4.65 M USD
DENNER ALEXANDER J
Director
+ 505100
9.2 USD
3 years ago
Feb 26, 2021
Sell 12.7 K USD
Shetzline Michael
CMO, SVP & Head of Drug Devt.
- 1398
9.11 USD
3 years ago
Feb 26, 2021
Sell 27.7 K USD
Shetzline Michael
CMO, SVP & Head of Drug Devt.
- 3041
9.11 USD
3 years ago
Feb 26, 2021
Sell 24.3 K USD
Rickard Jason
SVP, Chief Operating Officer
- 2668
9.11 USD
3 years ago
Feb 26, 2021
Sell 14.8 K USD
Rickard Jason
SVP, Chief Operating Officer
- 1627
9.11 USD
3 years ago
Feb 26, 2021
Sell 29.1 K USD
Rickard Jason
SVP, Chief Operating Officer
- 3197
9.11 USD
3 years ago
Feb 26, 2021
Sell 56.1 K USD
Rickard Jason
SVP, Chief Operating Officer
- 6159
9.11 USD
3 years ago
Feb 26, 2021
Bought 26.7 K USD
Owens Edward P
Director
+ 3000
8.9 USD
3 years ago
Feb 26, 2021
Sell 23.5 K USD
MCCOURT Thomas A
President
- 2582
9.11 USD
3 years ago
Feb 26, 2021
Sell 16.7 K USD
MCCOURT Thomas A
President
- 1838
9.11 USD
3 years ago
Feb 26, 2021
Sell 93.5 K USD
MCCOURT Thomas A
President
- 10265
9.11 USD
3 years ago
Feb 26, 2021
Sell 73.7 K USD
Mallon Mark
Chief Executive Officer
- 8093
9.11 USD
3 years ago
Feb 26, 2021
Sell 206 K USD
Mallon Mark
Chief Executive Officer
- 22582
9.11 USD
3 years ago
Feb 26, 2021
Sell 12.7 K USD
Kilroy Conor
SVP, GC & Secretary
- 1399
9.11 USD
3 years ago
Feb 26, 2021
Sell 13.4 K USD
Kilroy Conor
SVP, GC & Secretary
- 1474
9.11 USD
3 years ago
Feb 26, 2021
Sell 20.7 K USD
Kilroy Conor
SVP, GC & Secretary
- 2268
9.11 USD
3 years ago
Feb 26, 2021
Sell 16.8 K USD
Kilroy Conor
SVP, GC & Secretary
- 1848
9.11 USD
3 years ago
Feb 26, 2021
Sell 24.2 K USD
Consylman Gina
SVP, CFO & Treasurer
- 2657
9.11 USD
3 years ago
Feb 26, 2021
Sell 23 K USD
Consylman Gina
SVP, CFO & Treasurer
- 2527
9.11 USD
3 years ago
Feb 26, 2021
Sell 56.9 K USD
Consylman Gina
SVP, CFO & Treasurer
- 6242
9.11 USD
3 years ago
Feb 26, 2021
Sell 63.6 K USD
Consylman Gina
SVP, CFO & Treasurer
- 6980
9.11 USD
3 years ago
Feb 25, 2021
Bought 45.6 K USD
Owens Edward P
Director
+ 5000
9.11 USD
3 years ago
Feb 24, 2021
Bought 64.8 K USD
Owens Edward P
Director
+ 7000
9.26 USD
3 years ago
Dec 04, 2020
Sell 70.5 K USD
MacDonald Kelly
Chief Accounting Officer
- 5639
12.5 USD
4 years ago
Nov 11, 2020
Sell 41.8 K USD
MacDonald Kelly
Chief Accounting Officer
- 3561
11.75 USD
4 years ago
Nov 09, 2020
Sell 4.3 K USD
Rickard Jason
SVP, Chief Operating Officer
- 394
10.92 USD
4 years ago
Nov 06, 2020
Sell 21.1 K USD
MacDonald Kelly
Chief Accounting Officer
- 1872
11.25 USD
4 years ago
Nov 09, 2020
Sell 9.01 K USD
MacDonald Kelly
Chief Accounting Officer
- 825
10.92 USD
4 years ago
Nov 09, 2020
Sell 1.09 K USD
MacDonald Kelly
Chief Accounting Officer
- 100
10.92 USD
4 years ago
Nov 09, 2020
Sell 6.54 K USD
Kilroy Conor
SVP, GC & Secretary
- 599
10.92 USD
4 years ago
Nov 09, 2020
Sell 2.59 K USD
Kilroy Conor
SVP, GC & Secretary
- 237
10.92 USD
4 years ago
Nov 09, 2020
Sell 9.01 K USD
Consylman Gina
SVP, CFO & Treasurer
- 825
10.92 USD
4 years ago
Nov 09, 2020
Sell 6.44 K USD
Consylman Gina
SVP, CFO & Treasurer
- 590
10.92 USD
4 years ago
Oct 08, 2020
Sell 238 K USD
MacDonald Kelly
Chief Accounting Officer
- 22714
10.5 USD
4 years ago
Sep 08, 2020
Sell 77.7 K USD
McHugh Julie
Director
- 7950
9.77 USD
4 years ago
Aug 17, 2020
Sell 6.99 K USD
Rickard Jason
SVP, Chief Operating Officer
- 689
10.14 USD
4 years ago
Aug 17, 2020
Sell 5.83 K USD
MacDonald Kelly
Chief Accounting Officer
- 575
10.14 USD
4 years ago
Jun 10, 2020
Sell 114 K USD
OLANOFF LAWRENCE S
Director
- 11350
10.06 USD
4 years ago
May 11, 2020
Sell 5.28 K USD
Rickard Jason
SVP, Chief Operating Officer
- 510
10.35 USD
4 years ago
May 11, 2020
Sell 17.6 K USD
MCCOURT Thomas A
President
- 1697
10.35 USD
4 years ago
May 11, 2020
Sell 240 K USD
Mallon Mark
Chief Executive Officer
- 23206
10.35 USD
4 years ago
May 11, 2020
Sell 5.78 K USD
MacDonald Kelly
Chief Accounting Officer
- 558
10.35 USD
4 years ago
May 11, 2020
Sell 6.16 K USD
MacDonald Kelly
Chief Accounting Officer
- 595
10.35 USD
4 years ago
May 11, 2020
Sell 1.64 K USD
Kilroy Conor
SVP, GC & Secretary
- 158
10.35 USD
4 years ago
May 11, 2020
Sell 5.78 K USD
Kilroy Conor
SVP, GC & Secretary
- 558
10.35 USD
4 years ago
Feb 21, 2020
Sell 92.8 K USD
Mallon Mark
Chief Executive Officer
- 7983
11.63 USD
4 years ago
Feb 24, 2020
Sell 11.2 USD
Mallon Mark
Chief Executive Officer
- 1
11.25 USD
4 years ago
Feb 21, 2020
Sell 26.9 K USD
MCCOURT Thomas A
President
- 2312
11.63 USD
4 years ago
Feb 21, 2020
Sell 21.7 K USD
MCCOURT Thomas A
President
- 1865
11.63 USD
4 years ago
Feb 21, 2020
Sell 3.51 K USD
MacDonald Kelly
Chief Accounting Officer
- 302
11.63 USD
4 years ago
Feb 21, 2020
Sell 5.86 K USD
MacDonald Kelly
Chief Accounting Officer
- 504
11.63 USD
4 years ago
Feb 21, 2020
Sell 3.52 K USD
MacDonald Kelly
Chief Accounting Officer
- 303
11.63 USD
4 years ago
Feb 21, 2020
Sell 9.22 K USD
MacDonald Kelly
Chief Accounting Officer
- 793
11.63 USD
4 years ago
Feb 21, 2020
Sell 3.52 K USD
MacDonald Kelly
Chief Accounting Officer
- 303
11.63 USD
4 years ago
Feb 21, 2020
Sell 19.7 K USD
MacDonald Kelly
Chief Accounting Officer
- 1695
11.63 USD
4 years ago
Feb 21, 2020
Sell 32 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 2753
11.63 USD
4 years ago
Feb 21, 2020
Sell 39.7 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 3410
11.63 USD
4 years ago
Feb 21, 2020
Sell 34.7 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 2984
11.63 USD
4 years ago
Feb 21, 2020
Sell 71.9 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 6181
11.63 USD
4 years ago
Feb 21, 2020
Sell 17.6 K USD
Consylman Gina
SVP, CFO & Treasurer
- 1510
11.63 USD
4 years ago
Feb 21, 2020
Sell 26.2 K USD
Consylman Gina
SVP, CFO & Treasurer
- 2252
11.63 USD
4 years ago
Feb 21, 2020
Sell 29.7 K USD
Consylman Gina
SVP, CFO & Treasurer
- 2558
11.63 USD
4 years ago
Feb 21, 2020
Sell 71.9 K USD
Consylman Gina
SVP, CFO & Treasurer
- 6181
11.63 USD
4 years ago
Jan 31, 2020
Sell 723 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 60000
12.05 USD
4 years ago
Jan 24, 2020
Sell 254 K USD
MCCOURT Thomas A
President
- 20000
12.71 USD
4 years ago
Jan 23, 2020
Sell 755 K USD
Currie Mark G
Director
- 60000
12.59 USD
4 years ago
Jan 16, 2020
Sell 114 K USD
Currie Mark G
Director
- 8888
12.8 USD
5 years ago
Nov 08, 2019
Sell 9.68 K USD
MacDonald Kelly
Chief Accounting Officer
- 880
11 USD
5 years ago
Nov 08, 2019
Sell 1.18 K USD
MacDonald Kelly
Chief Accounting Officer
- 107
11 USD
5 years ago
Nov 08, 2019
Sell 9.68 K USD
Consylman Gina
SVP, CFO & Treasurer
- 880
11 USD
5 years ago
Nov 08, 2019
Sell 6.93 K USD
Consylman Gina
SVP, CFO & Treasurer
- 630
11 USD
5 years ago
Aug 30, 2019
Sell 2.03 M USD
MCCOURT Thomas A
President
- 220000
9.24 USD
5 years ago
Aug 16, 2019
Sell 1.92 K USD
Consylman Gina
SVP, CFO & Treasurer
- 212
9.04 USD
5 years ago
Jul 26, 2019
Sell 200 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 20000
10 USD
5 years ago
Jun 05, 2019
Sell 22.5 K USD
OLANOFF LAWRENCE S
Director
- 2000
11.25 USD
5 years ago
Jun 05, 2019
Sell 16.9 K USD
McHugh Julie
Director
- 1500
11.26 USD
5 years ago
May 10, 2019
Sell 42.7 K USD
MCCOURT Thomas A
President
- 4055
10.53 USD
5 years ago
May 10, 2019
Sell 42.7 K USD
Gilbert Halley E
Chief Admin Officer & SVP
- 4055
10.53 USD
5 years ago
May 10, 2019
Sell 42.7 K USD
Currie Mark G
Director
- 4055
10.53 USD
5 years ago
May 10, 2019
Sell 42.7 K USD
Consylman Gina
SVP, CFO & Treasurer
- 4055
10.53 USD
5 years ago
Mar 07, 2019
Sell 3 M USD
Currie Mark G
Chief Scientific Officer
- 225500
13.29 USD
5 years ago
Mar 08, 2019
Sell 651 K USD
Currie Mark G
Chief Scientific Officer
- 49500
13.15 USD
5 years ago
Mar 05, 2019
Sell 21.6 K USD
McHugh Julie
Director
- 1500
14.38 USD
5 years ago
Mar 05, 2019
Sell 28.8 K USD
OLANOFF LAWRENCE S
Director
- 2000
14.41 USD
5 years ago
Feb 20, 2019
Sell 17.3 K USD
MCCOURT Thomas A
Chief Commercial Officer
- 1212
14.31 USD
5 years ago
Feb 20, 2019
Sell 28 K USD
MCCOURT Thomas A
Chief Commercial Officer
- 1957
14.31 USD
5 years ago
Feb 20, 2019
Sell 23.3 K USD
MCCOURT Thomas A
Chief Commercial Officer
- 1631
14.31 USD
5 years ago
Feb 21, 2019
Sell 143 USD
MCCOURT Thomas A
Chief Commercial Officer
- 10
14.32 USD
5 years ago
Feb 21, 2019
Sell 243 USD
MCCOURT Thomas A
Chief Commercial Officer
- 17
14.32 USD
5 years ago
Feb 21, 2019
Sell 200 USD
MCCOURT Thomas A
Chief Commercial Officer
- 14
14.32 USD
5 years ago
Feb 20, 2019
Sell 30.7 K USD
Gilbert Halley E
Chief Legal Officer
- 2143
14.31 USD
5 years ago
Feb 20, 2019
Sell 34.7 K USD
Gilbert Halley E
Chief Legal Officer
- 2423
14.31 USD
5 years ago
Feb 20, 2019
Sell 42.7 K USD
Gilbert Halley E
Chief Legal Officer
- 2982
14.31 USD
5 years ago
Feb 20, 2019
Sell 37.3 K USD
Gilbert Halley E
Chief Legal Officer
- 2609
14.31 USD
5 years ago
Feb 21, 2019
Sell 258 USD
Gilbert Halley E
Chief Legal Officer
- 18
14.32 USD
5 years ago
Feb 21, 2019
Sell 286 USD
Gilbert Halley E
Chief Legal Officer
- 20
14.32 USD
5 years ago
Feb 21, 2019
Sell 358 USD
Gilbert Halley E
Chief Legal Officer
- 25
14.32 USD
5 years ago
Feb 21, 2019
Sell 315 USD
Gilbert Halley E
Chief Legal Officer
- 22
14.32 USD
5 years ago
Feb 20, 2019
Sell 23.3 K USD
Currie Mark G
Chief Scientific Officer
- 1631
14.31 USD
5 years ago
Feb 21, 2019
Sell 186 USD
Currie Mark G
Chief Scientific Officer
- 13
14.32 USD
5 years ago
Feb 20, 2019
Sell 4.55 K USD
Consylman Gina
Chief Financial Officer
- 318
14.31 USD
5 years ago
Feb 20, 2019
Sell 16 K USD
Consylman Gina
Chief Financial Officer
- 1119
14.31 USD
5 years ago
Feb 20, 2019
Sell 28 K USD
Consylman Gina
Chief Financial Officer
- 1957
14.31 USD
5 years ago
Feb 20, 2019
Sell 32 K USD
Consylman Gina
Chief Financial Officer
- 2237
14.31 USD
5 years ago
Feb 21, 2019
Sell 28.6 USD
Consylman Gina
Chief Financial Officer
- 2
14.32 USD
5 years ago
Feb 21, 2019
Sell 129 USD
Consylman Gina
Chief Financial Officer
- 9
14.32 USD
5 years ago
Feb 21, 2019
Sell 243 USD
Consylman Gina
Chief Financial Officer
- 17
14.32 USD
5 years ago
Feb 21, 2019
Sell 258 USD
Consylman Gina
Chief Financial Officer
- 18
14.32 USD
5 years ago
Jan 24, 2019
Sell 381 K USD
Hecht Peter M
Chief Executive Officer
- 30000
12.7 USD
5 years ago
Jan 23, 2019
Sell 380 K USD
Hecht Peter M
Chief Executive Officer
- 30000
12.66 USD
5 years ago
Jan 25, 2019
Sell 361 K USD
Hecht Peter M
Chief Executive Officer
- 29551
12.23 USD
5 years ago
Dec 06, 2018
Sell 18.7 K USD
McHugh Julie
Director
- 1500
12.46 USD
5 years ago
Dec 06, 2018
Sell 24.9 K USD
OLANOFF LAWRENCE S
Director
- 2000
12.47 USD
6 years ago
Nov 09, 2018
Sell 16 K USD
Consylman Gina
Chief Financial Officer
- 1358
11.81 USD
6 years ago
Oct 04, 2018
Sell 1.69 M USD
Currie Mark G
Chief Scientific Officer
- 94456
17.94 USD
6 years ago
Oct 05, 2018
Sell 2.04 M USD
Currie Mark G
Chief Scientific Officer
- 116651
17.53 USD
6 years ago
Oct 04, 2018
Sell 416 K USD
Currie Mark G
Chief Scientific Officer
- 22194
18.75 USD
6 years ago
Sep 05, 2018
Sell 38.2 K USD
OLANOFF LAWRENCE S
Director
- 2000
19.1 USD
6 years ago
Sep 05, 2018
Sell 28.7 K USD
McHugh Julie
Director
- 1500
19.1 USD
6 years ago
Aug 24, 2018
Sell 1.2 M USD
Currie Mark G
Chief Scientific Officer
- 65000
18.39 USD
7. News
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be a. businesswire.com - 3 days ago
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. zacks.com - 1 week ago
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Conference Call Participants Amy Li - Jefferies David Amsellem - Piper Sandler Jason Butler - Citizens JMP Mohit Bansal - Wells Fargo Operator Thank you for standing by. My name is Louella, and I will be your conference operator today. seekingalpha.com - 1 week ago
Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. zacks.com - 1 week ago
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, evaluating the treatment effect of apraglutide by baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure. businesswire.com - 2 weeks ago
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ir. businesswire.com - 3 weeks ago
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - Piper Sandler Amy Li - Jefferies Mohit Bansal - Wells Fargo Jason Butler - Citizens JMP Tim Chiang - Capital One Operator Thank you for standing by. My name, Celine, and I will be your conference operator today. seekingalpha.com - 3 months ago
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. zacks.com - 3 months ago
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago. zacks.com - 3 months ago
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
New Strong Sell Stocks for July 23rd ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024. zacks.com - 3 months ago
New Strong Sell Stocks for July 5th ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024. zacks.com - 4 months ago
8. Profile Summary

Ironwood Pharmaceuticals, Inc. IRWD

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 674 M
Dividend Yield 0.00%
Description Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Contact 100 Summer Street, Boston, MA, 02110 https://www.ironwoodpharma.com
IPO Date Feb. 3, 2010
Employees 267
Officers Mr. Mike Nanfito Vice President of Sales & Sales Excellence Mr. Sravan Kumar Emany Senior Vice President, Chief Financial Officer & Chief Operating Officer Mr. Greg Martini Vice President of Strategic Finance & Investor Relations Ms. Beth Calitri Vice President of Corporate Communications & Media Relations Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. Vice President & Global Head of Technical Operations Mr. John Minardo Senior Vice President, Chief Legal Officer & Secretary Dr. Michael Shetzline M.D., Ph.D. Chief Medical Officer, Senior Vice President and Head of Research & Drug Development Mr. Andrew Davis Senior Vice President & Chief Business Officer Mr. Ronald Silver Corporate Controller & Principal Accounting Officer Mr. Thomas A. McCourt Chief Executive Officer & Director